https://www.selleckchem.com/pr....oducts/act001-dmamcl
SDHB may be a potential prognostic marker and therapeutic target for ccRCC.Background The best response and survival outcomes between advanced melanoma patients treated with the anti-PD-1 monotherapy vary greatly, rendering a risk model in need to optimally stratify patients based on their likelihood to benefit from the said treatment. Methods We performed an ad hoc analysis of 89 advanced melanoma patients treated with the anti-PD-1 monotherapy from two prospective clinical trials at the Peking University Cancer Hospital from Apr
Like
Comment
Share
